Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. [electronic resource]
Producer: 20181108Description: 174-183 p. digitalISSN:- 1873-264X
- Acrylamides
- Afatinib
- Aniline Compounds
- Antineoplastic Agents -- blood
- Carcinoma, Non-Small-Cell Lung -- blood
- Chromatography, High Pressure Liquid
- Crizotinib
- Drug Monitoring -- methods
- Drug Stability
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- blood
- Humans
- Indoles -- blood
- Limit of Detection
- Lung Neoplasms -- blood
- Piperazines -- blood
- Protein Kinase Inhibitors -- blood
- Pyrazoles -- blood
- Pyridines -- blood
- Quinazolines -- blood
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Reproducibility of Results
- Sensitivity and Specificity
- Tandem Mass Spectrometry
No physical items for this record
Publication Type: Journal Article; Validation Study
There are no comments on this title.
Log in to your account to post a comment.